Posted on June 3: MBA student receives inaugural award for excellence in health services management

Sabrina Ciardelli, MBA '03 will be awarded the Allan J. Greve  St. Joseph's Healthcare Medal for Excellence in Health Services Management at the DeGroote School of Business Convocation today. The prize of a gold medal and $1,500 is awarded for the highest academic performance of a graduating student in the Health Services Management (HSM) stream in the MBA program. "I am very honoured to be the first recipient of this prestigious award. It is also a great honour to have an association with Mr. Greve, who has been such an influential leader in the healthcare sector," Ciardelli remarked. The MBA student was selected for this distinction as a result of her stellar academic performance  she achieved the highest cumulative grade point average ever recorded within the HSM program. Ciardelli also completed a double major, pairing health services with marketing. "Sabrina is an exemplary student. Her grade point average was well above the rest of the class, and she showed strong leadership skills within the classroom and during her work term placements as well," explains Dr. D. Wayne Taylor, director of the Health Services Management stream. In addition to her strong academic performance, Ciardelli found time to sit on student committees and act as a mentor for new MBA students. She is currently employed as a product manager for Stryker, a health care products manufacturer. The medal is named in honour of Allan J. Greve, former president and CEO of St. Joseph's Healthcare Hamilton. The award recognizes Greve's success in establishing St. Joseph's as a major academic health sciences centre renowned for its strong management, clinical and fiscal performance, and innovation and academic excellence. Greve continues to be an important advisor to government, industry and health care institutions. Allan Greve will take part in the Convocation procession and ceremony.

Read More

Posted on June 2: McMaster study shows cancer patients benefit from new method of bone analysis

Data on the effectiveness of zoledronic acid for the treatment of bone metastases that stem from various cancer types has contributed to a better understanding of multiple bone complications, according to a study led by Pierre Major, a medical oncologist at McMaster University, and presented at the American Society of Clinical Oncology (ASCO) meeting in Chicago, Illinois, USA. Research indicates many patients with advanced cancer develop bone metastasis, the spread of cancerous cells from the original tumour to bones. Many of these patients are at risk of developing multiple bone complications including bone pain, pathologic fractures, a need for radiation or surgery to their bones, spinal cord compression, and hypercalcaemia. These painful, debilitating complications can significantly impact the daily lives of patients and caregivers. Understanding the cumulative burden of these bone complications over the entire course of follow-up allows physicians to determine the best treatment options for their patients. The data confirm superior results from treatment with zoledronic acid infusions on the occurrence of first and subsequent bone complications. The simple graphical summaries of cumulative disease burden, obtained from the new analysis, have direct relevance for health economic considerations. Major, associate professor of medicine at McMaster, and Richard Cook, University of Waterloo, used a new method to analyze the growing burden of pain and morbidity from bone complications in patients with breast, prostate or lung cancer, or other solid tumors. The new analysis helps doctors gain insight into the effects of treatment and prevention of the debilitating effects of complications to the bone. This method adjusted for survival and patient dropout information. "Metastasis to bone causes significant pain, adversely affects quality of life and substantially raises healthcare costs for patients with a wide range of tumors," said Major. "As patients live longer, it becomes that much more important for physicians to understand the long-term risks from bone metastases and subsequent complications to help avoid these problems and to manage pain and suffering from these complications that follow."

Read More